https://scholars.lib.ntu.edu.tw/handle/123456789/579717
標題: | Clinical outcome of subcentimeter non-small cell lung cancer after VATS resection: Single institute experience with 424 patients | 作者: | Tsou, Kuan-Chuan HSAO-HSUN HSU TUNG-MING TSAI KE-CHENG CHEN JIN-SHING CHEN |
公開日期: | 2020 | 出版社: | Elsevier B.V. | 卷: | 119 | 期: | 1P3 | 起(迄)頁: | 399-405 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background/purpose: Non-small cell lung cancer (NSCLC) presenting as subcentimeter lung tumor was increasing due to the popularity of low dose CT in recent years. However, the ideal surgical management is still controversial. We utilized our lung cancer surgery database to study the important issue, aiming to find the optimal treatment with VATS. Methods: From January 2010 to December 2015, we retrospectively reviewed the clinical characteristics, staging, operation methods, and outcomes of 424 patients with subcentimeter lung cancer. Three groups distinguished by surgical methods were compared. Results: There are 273, 57, and 94 undergoing VATS wedge resection, segmentectomy, and lobectomy, respectively. Of the nine recurrence or metastasis events, seven and two occurred within the wedge resection and lobectomy groups, respectively. The average follow-up time is 779 days (2.16 years). Furthermore, 97.4%, 100%, and 97.9% of patients in the wedge resection, segmentectomy, and lobectomy groups, respectively remained tumor-free during follow-up. The complication rate of approximately 1.5% did not differ significantly between the three groups. An obvious difference in disease-free survival between the three groups (p-value = 0.027; −2 log likelihood score and chi-square test). No cases of recurrence or metastasis were observed in the segmentectomy group. Conclusion: Lung cancer with subcentimeter size will be more and more encountered. VATS plays an important role in the management with good post-operative outcome, whether with wedge resection, segmentectomy and lobectomy. However, VATS segmentectomy can deliver 100% overall survival and progression-free survival in our series. Further randomized controlled trial should be conducted to prove the concept. © 2019 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069803456&doi=10.1016%2fj.jfma.2019.07.004&partnerID=40&md5=cac5e5ec8fb790d3b390ee964510f6bf https://scholars.lib.ntu.edu.tw/handle/123456789/579717 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2019.07.004 |
顯示於: | 醫學院附設癌醫中心醫院(臺大癌醫) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。